Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta‐analysis

OBJECTIVES: For patients with type 2 diabetes, newer antihyperglycaemic agents (AHA), including the dipeptidyl peptidase IV inhibitors (DPP4i), glucagon‐like peptide‐1 receptor agonists (GLP1RA) and sodium glucose co‐transporter 2 inhibitors (SGLT2i) offer a lower risk of hypoglycaemia relative to s...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamalinia, Sanaz, Josse, Robert G., Donio, Patrick J., Leduc, Lindsay, Shah, Baiju R., Tobe, Sheldon W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947712/
https://www.ncbi.nlm.nih.gov/pubmed/31922027
http://dx.doi.org/10.1002/edm2.100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947712/
https://www.ncbi.nlm.nih.gov/pubmed/31922027
http://dx.doi.org/10.1002/edm2.100

Ejemplares similares